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AbstrACt
Objectives Compare hormonal contraceptive use, 
birth and abortion rates among teenagers in the Nordic 
countries. A secondary aim was to explore plausible 
explanations for possible differences between countries.
Design Ecological study using national registry data 
concerning births and abortions among all women aged 
15–19 years residing in Denmark, Finland, Iceland, 
Norway and Sweden 2008–2015. Age-specific data on 
prescriptions for hormonal contraceptives for the period 
2008–2015 were obtained from national databases in 
Denmark, Norway and Sweden.
setting Denmark, Finland, Iceland, Norway and Sweden.
Participants Women 15–19 years old in all Nordic 
countries (749 709) and 13–19 years old in Denmark, 
Norway and Sweden (815 044).
results Both annual birth rates and abortion rates fell 
in all the Nordic countries during the study period. The 
highest user rate of hormonal contraceptives among 
15–19-year-olds was observed in Denmark (from 51% to 
47%) followed by Sweden (from 39% to 42%) and Norway 
(from 37% to 41%). Combined oral contraceptives were 
the most commonly used methods in all countries. The use 
of long-acting reversible contraceptives (LARC), implants 
and the levonorgestrel-releasing intrauterine systems, 
were increasing, especially in Sweden and Norway. In the 
subgroup of 18–19-year-old teenagers, the user rates of 
hormonal contraceptives varied between 63% and 61% in 
Denmark, 56% and 61% in Norway and 54% and 56% in 
Sweden. In the same subgroup, the steepest increase of 
LARC was seen, from 2% to 6% in Denmark, 2% to 9% in 
Norway and 7% to 17% in Sweden.
Conclusions Birth and abortion rates continuously 
declined in the Nordic countries among teenagers. There 
was a high user rate of hormonal contraceptives, with an 
increase in the use of LARC especially among the oldest 
teenagers.
IntrODuCtIOn  
Teenage pregnancy is regarded as a challenge 
both to society and the teenager.1 Adolescent 
pregnancy and motherhood is associated with 
low socioeconomic status, early school leaving 
and poor health of the mother during and 
after pregnancy.2–6 Also, the child of a teenage 
mother is at risk both during the perinatal 
period and in the long-term.2 Socioeconomic 
deprivation is considered to be both an effect 
of and a risk factor for teenage births. Hence, 
ill health and low socioeconomic status are 
often disseminated across generations.6 7 
Women experiencing teenage motherhood 
or teenage abortion are also at risk of having 
another unplanned pregnancy.8–10 
In the USA and Europe, the rates of teenage 
pregnancies are declining,11 but there is a large 
variation both between the USA and Europe 
and within the European continent.12 The 
outcome of pregnancies differs greatly, where 
in some regions, most of the teenage preg-
nancies end with an induced abortion, while 
in others, a pregnancy is usually continued 
to term. Although the USA has witnessed a 
steadily declining teenage pregnancy rate 
(57/1000 in 2011), it is still comparable to 
the highest rates seen in the east-European 
countries. For example, an incidence of 
60/1000 of adolescent pregnancy has recently 
been reported from Romania and Bulgaria.12 
In Northern Europe, pregnancy rates vary 
between high levels of pregnancies and births 
in England and Wales (47/1000 in 2011) and 
much lower overall pregnancy rates in the 
Nordic countries and Ireland.12–14
strengths and limitations of this study
 ► The main strength of this study was the use of na-
tional register data, including all adolescents in the 
Nordic countries.
 ► In this study, data on redeemed prescriptions have 
been used since it has been shown to be more reli-
able than self-reported use of contraceptives.
 ► Non-hormonal contraceptives are not registered in 
any of the national databases and hence were not 
included in this study.
 ► Since personal identification data are not recorded 
for contraceptive sales in Finland and Iceland, use 
of hormonal contraceptives were only available from 
Denmark, Norway and Sweden.
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The declining rate of teenage pregnancy in the Nordic 
countries has been documented in several studies.15–17 
It has been suggested that an increasing availability 
of contraceptives is one of the reasons for the decline. 
Patterns of contraceptive use among teenagers have been 
described in individual Nordic countries16 18 19 and as part 
of European surveys.20 21 However, recent and compre-
hensive studies, including data on both pregnancies 
and contraceptive use among all Nordic teenagers, are 
lacking.
The aim of this study was to compare hormonal contra-
ceptive use, birth and abortion rates among teenagers 
in the Nordic countries. A secondary aim was to explore 
plausible explanations for possible differences between 
countries.
MAterIAl AnD MethODs
National data on abortion and birth rates among teen-
agers were compiled from the five Nordic countries, 
Denmark, Finland, Iceland, Norway and Sweden, from 
2000 to 2015.
Data regarding the use of hormonal contraceptives for 
the period 2008–2015 were only available from Denmark, 
Norway and Sweden as personal identification data are 
not recorded for contraceptive sales in Finland and 
Iceland.
Information on birth and abortion rates were collected 
from the National Health Registries22 and the Tigrab 
Database23 in Denmark, The National Institute for Health 
and Welfare in Finland,24 the Directorate of Health in 
Iceland,25 the Norwegian Institute of Public Health26 and 
the National Board of Health and Welfare in Sweden.27 
Birth and abortion rates were expressed as the number 
of births or abortions/1000 women and year in a certain 
age group according to international practice. When 
displaying the overall teenage birth and abortion rates, 
all births or abortions during 1 year among women ≤19 
years of age were included. Even though there is a small 
number of births and abortions among women younger 
than 15 years of age, the age group 15–19 was still used 
as a denominator in accordance with international prac-
tice.28 Age was further categorised into three groups 
(13–14, 15–17 and 18–19 years).
In Sweden, the collection of abortion data were tempo-
rarily stopped in 2013. When collection started again 
in 2014, only data for 5-year intervals of age were avail-
able; thus, Sweden was not able to provide data for the 
subgroups of 13–14, 15–17 and 18–19-year-olds from 2013 
and onwards.
National data on redeemed prescriptions of hormonal 
contraceptives in the Nordic countries were collected 
from the Danish National Registry of Medicinal Product 
Statistics,29 the Norwegian Prescription Database30 and 
the National Board of Health and Welfare in Sweden.27 
The collected data provide information on sold packages 
or items of different types of contraceptives expressed 
as defined daily doses (DDD). Use of combined oral 
contraceptives (COC), progestogen-only pills (POP), the 
contraceptive patch, the vaginal ring and the injection 
were expressed as DDD per 100 women-years (%). To be 
able to compare the levonorgestrel-releasing intrauterine 
system (LNG-IUS) with the other contraceptive methods, 
the mean duration of use for the two LNG-IUSs avail-
able during the study period were set to 431 and 2 years, 
respectively.32 Similarly, we calculated duration of use for 
the etonogestrel implant to be 2 years according to the 
average duration of use reported in previous studies.31 33 
All prescribed hormonal contraceptives to women ≤19 
years of age were included when user rates among 
15–19-year-olds were estimated, although a small number 
of prescriptions were for women below 15 years of age. As 
for abortion and birth rates, we also estimated hormonal 
contraceptive user rates for the age groups 13–14, 15–17 
and 18–19 years.
Use of copper intrauterine device (IUD), condoms, 
diaphragms and fertility awareness methods was not 
estimated since these methods are not registered in any 
national databases. Since personal identification data are 
not recorded for hormonal emergency contraceptives, 
these methods are not included either.
Since all variables were collected on a group level from 
anonymised data including all teenagers, also teenagers 
who were infertile, not heterosexually active, pregnant or 
wished to get pregnant were part of the study population.
Demographic data for the Nordic countries were 
obtained from the database Facts about the Nordic 
region.34
ethical considerations
All data included in the study was either already in the 
public domain or anonymised on receipt.
The legal aspects of utilisation of registry data for study 
purposes in Denmark and Norway were performed in 
accordance with national legislation. For Norway, the 
board of the Norwegian Prescription Database reviewed 
the protocol and gave permission for use of the data. 
Studies using anonymous data from nationwide registers 
are by Norwegian legislation exempted from the need 
of institutional regulatory board approvals and written 
informed consent from the patients. The specific permis-
sions from the relevant body were in Denmark achieved 
from Datatilsynet (journal no 2010-41-4778).
In Finland, Iceland and Sweden, no permission was 
required as these data are publicly available from the 
national bodies of these countries. Since patients were 
not directly involved in the study and only anonymised 
data were used, no ethical consent was needed.
Patient and public involvement
There was no direct involvement in the study by patients, 
since only aggregated and anonymised data were used.
statistical methods
In these purely descriptive analyses, no CIs were calcu-
lated for the country-specific rates. Since all female 
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teenagers in each specific age group were included, even 
small differences were highly significant.
results
Population
In 2015, the overall study population comprised 749 
709 women 15–19 years old in the Nordic countries. 
When restricting the analysis to 13–19 years old women 
in Denmark, Norway and Sweden, the study population 
comprised 815 044 teenagers (2015).
births, abortions and use of hormonal contraception among 
teenagers 15–19 years
The birth rates fell from 8 to 3/1000 women 15–19 years 
in Denmark, 10 to 6 in Finland, 23 to 8 in Iceland, 12 to 5 
in Norway and 7 to 4 in Sweden from 2000 through 2015 
(figure 1A).
The abortion rates fell from 14 to 11/1000 in women 
aged 15–19 years in Denmark, 15 to 8 in Finland, 25 to 13 
in Iceland, 20 to 8 in Norway and 20 to 14 per 1000 teen-
agers in Sweden (figure 1B). Both birth and abortion 
rates decreased which resulted in an overall decline of 
teenage pregnancy rates in all countries.
The overall use of hormonal contraceptives varied 
between 51% and 47% in Denmark, 37% and 41% 
in Norway and 39% and 42% in Sweden from 2008 
through 2015 (figure 2A). COC was the most commonly 
used contraceptive method in all countries, but more 
frequently used among Danish teenagers, while POP were 
more common in Sweden (7% to 5%) and Norway (3% 
to 4%). The use of long-acting reversible contraceptives 
(LARC), including implants and the LNG-IUS, increased 
from 2% to 4% in Denmark, 1% to 7% in Norway and 5% 
to 12% in Sweden. In Sweden and Denmark, the increase 
of LARC consisted mainly of a higher use of LNG-IUS, 
while in Norway the increase of LARC was mainly due to 
a higher use of implants (figure 2B).
Figure 1 (A) Births/1000 women aged 15–19 during 2000–2015 in the Nordic countries. (B) Abortions/1000 women aged 15–
19 during 2000–2015 in the Nordic countries. Age-stratified abortion rates were not available for 2013 in Sweden. 
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Age-stratified births, abortions and use of hormonal 
contraceptives in Denmark, norway and sweden, 2008–2015
The birth and abortion rates over the years 2008 through 
2015 were very low among 13–14-year-old teenagers in all 
three countries. Births varied between 0 and 0.1 per 1000 
teenagers a year in all three countries. Abortion rates 
varied between 1.7 and 0.5 in Denmark, 0.3 and 0.4 in 
Norway and 1.9 and 1.3 per 1000 teenagers in Sweden 
(during 2008–2012 in Sweden, no data available 2013–
2015). The use of hormonal contraceptives was also very 
low in this age group (from 5% to 3% in Denmark, 1% in 
Norway and from 1% to 2% in Sweden) (figure 3A and 
figure 4A).
Birth rates varied around 2 per 1000 teenagers yearly 
in all three countries among 15–17-year-olds. The abor-
tion rates in the same age group declined from 12 to 6 in 
Denmark, 8 to 4 in Norway and 17 to 12 per 1000 teen-
agers in Sweden (during 2008–2012 in Sweden, no data 
available 2013–2015). Denmark had a markedly higher 
use of hormonal contraceptives (from 40% to 34%) than 
Norway (from 25% to 27%) and Sweden (from 29% 
to 30%) among 15–17-year-olds. Combined hormonal 
contraceptives (CHC) was the most commonly used 
method in all countries. Use of LARC, including implants 
and LNG-IUS, increased from 2% to 3% in Denmark, 1% 
to 6% in Norway and 4% to 9% in Sweden (figure 3B and 
figure 4B).
A more marked decrease of the birth rate was seen 
among 18–19-year-olds in Norway (from 20 to 10 per 1000 
teenagers) compared with the other two countries (from 
13 to 7 in Denmark and from 12 to 9 in Sweden), where 
Norway started off on a higher level in 2008. The abortion 
Figure 2 (A) Contraceptive use, birth and abortion rates among women aged 15–19 in Denmark, Norway and Sweden, 
2008–2015. (B) Use of long-acting reversible contraceptives (LARC including implants and levonorgestrel-releasing 
intrauterine systems), birth and abortion rates among women aged 15–19 in Denmark, Norway and Sweden, 2008–2015. Y1 
(left): use of hormonal contraception (%). Y2 (right): birth and abortion rates (number of women/1000 women and year). 
Age-stratified abortion rates were not available for 2013 in Sweden. COC, combined oral contraceptives; Injection, depot 
medroxyprogesterone acetate (DMPA); LNG-IUS, levonorgestrel-releasing intrauterine system; POP, middle-dose or low-dose 
progestogen-only pill. 
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rates in the same age group declined from 26 to 18 per 
1000 in Denmark, from 25 to 14 in Norway and 33 to 26 per 
1000 teenagers in Sweden (during 2008–2012 in Sweden, 
no data available 2013–2015). The overall user rates of 
hormonal contraceptives among teenagers 18–19 years of 
age varied between 63% and 61% in Denmark, 56% and 
61% in Norway and 54% and 56% in Sweden. CHC were 
the most commonly used method in all countries. Use of 
LARC, including implants and LNG-IUS, increased from 
2% to 6% in Denmark, 2% to 9% in Norway and 7% to 
17% in Sweden (figure 3C and figure 4C).
DIsCussIOn
Birth and abortion rates among teenagers in all the Nordic 
countries have declined between 2008 and 2015. During 
the same time period, more than half of the 18–19-year-old 
women were using hormonal contraception. The use of 
LARC increased, especially among 18–19-year-olds, while 
there was a small reduction in the use of CHC and POP. 
Birth and abortion rates were low in the Nordic countries 
compared with overall worldwide rates among teenagers.12 
Moreover, the decreasing rate of teenage births has not 
been offset by an increasing abortion rate.
Figure 3 (A-C) Contraceptive use, birth and abortion rates among women aged 13–19 in Denmark, Norway and Sweden, 
2008–2015, according to age groups. Please note the different scales. Y1 (left): use of hormonal contraception (%). Y2 (right): 
birth and abortion rates (number of abortion or births/1000 women). Age-stratified abortion rates were not available for 2013–15 
in Sweden. Ab rate, abortion rate; CHC, combined hormonal contraceptives (subgroups oral, vaginal and transdermal); Injection, 
depot medroxyprogesterone acetate (DMPA); LNG-IUS, levonorgestrel-releasing intrauterine system; POP, middle-dose or low-
dose progestogen-only pill.
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The strength of this study was the use of national 
register data, which included all adolescents in the 
Nordic countries. All the registries are considered reli-
able. However, redeemed prescriptions do not necessarily 
mean that the contraceptives actually have been used. 
Nevertheless, when assessing contraceptive use, phar-
macy claims have been shown to be more reliable than 
self-reported use, as women tend to overestimate their 
contraceptive use.35 Online purchases of pharmaceutical 
drugs without a registered prescription are not included 
in the study. Since prescribed hormonal contraceptives 
are available and affordable to most adolescents in the 
Nordic countries, the proportion of online purchases 
without a prescription is not considered to be significant. 
A limitation in this study was the lack of age-specific data 
on contraceptive use from Finland and Iceland.
Although declining, Sweden had the highest teenage 
abortion rate and the reasons for that are not obvious. 
The observed differences in overall user rates of hormonal 
contraceptives could not explain the differences in abor-
tion rates since, for example, Norway had a lower user 
rate than Sweden, but still had lower abortion rates.
The risk of unplanned pregnancies is determined by 
three main factors: the proportion of sexually active 
Figure 4 (A-C) Use of long-acting reversible contraceptives (LARC including implants and levonorgestrel-releasing intrauterine 
systems), birth and abortion rates among women aged 13–19 in Denmark, Norway and Sweden, 2008–2015, according to age 
groups. Please note the different scales. Y1 (left): use of LARC (%). Y2 (right): birth and abortion rates (number of abortion or 
births/1000 women). Age-stratified abortion rates were not available for 2013–2015 in Sweden. Ab rate, abortion rate; LNG-
IUS, levonorgestrel-releasing intrauterine system.
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women in the studied age group, the proportion of 
women using any contraceptive method and the efficacy 
of the contraceptive used.
Concerning sexual activity, a study including 65 000 
women in Denmark, Iceland, Norway and Sweden 
reported that the number of sexual partners and median 
age for first intercourse (16 years) was the same in all 
countries.36 However, the study only covers the years 
2004–2005. The declining pregnancy rate seen in all the 
Nordic countries during the study period could be due 
to postponed time of first intercourse and/or declining 
sexual activity among teenagers, but there are no recent 
studies to support or reject this statement.
Regarding the second identified factor, proportion of 
contraceptive users, there were only small differences 
between the three Nordic countries studied and the 
proportion did not increase more in countries with the 
steepest decrease in births and abortion rates. The timing 
of initiation of contraceptive use might play a role though 
since it has been shown that initiation before or at first 
intercourse is associated with lower future abortion rates 
compared with initiation after the first intercourse.37 
We were not able to estimate the proportion of women 
using other methods such as copper IUDs, condoms, 
fertility awareness methods and emergency contra-
ceptives. According to national16 18 38 and European 
studies,20 39 condoms are a frequently used contraceptive 
method among teenagers with pronounced user-depen-
dent efficacy. There might be differences in condom 
use between the Nordic countries that can influence the 
pregnancy rates.
The third important factor is the quality of the contra-
ceptive use. There is robust scientific evidence of the 
high efficacy of LARC methods.40 41 During the last 10–15 
years, the promotion of LARC as the most effective form 
of contraception has increased and it has been reflected 
in, for example, national guidelines on contraception. 
This recommendation also applies to teenagers. Norwe-
gian, Swedish and, to a lesser extent, Danish teenagers 
have increased their use of LARC (including LNG-IUS 
and implants) at the expense of CHC and POP during 
the most recent years. There was a shift towards recom-
mending LARC already in the guidelines for contracep-
tion in 2005 in Sweden, but in the updated guidelines 
from 2014, LARC was strongly recommended as a first 
option also for teenagers. Norway has made similar recent 
updates for recommendations of LARC. In 2014, also a 
smaller LNG-IUS (Jaydess) was introduced in the market 
as an IUS especially well suited for young women. It is 
likely that these actions are at least some of the reasons for 
the increasing use of LARC seen in this study, especially 
among 18–19-year-old women. During the same period of 
time, abortion rates in all the countries included in this 
study have reached their all-time low mark.
Sexual activity, contraceptive user rate and the quality 
of the contraceptive use can be influenced by a number 
of factors. Simultaneously, with the liberalisation of the 
abortion laws in the 1970s, the Nordic countries also 
focused on easy access to contraceptives, establishment 
of family planning services, youth clinics and sexuality 
education programmes. The implementation of these 
routines differed to some extent between countries. To 
ensure easy access to contraceptives, general practitioners 
in Denmark and Norway were given the main respon-
sibility of prescribing contraceptives, although since 
2006, public health nurses and midwives have also been 
granted authorisation to prescribe hormonal contracep-
tives. In Sweden, midwives have been the main prescriber 
since the 1970s. Unfortunately, they have, to a great 
extent, been left without medical advisors, which might 
influence their recommendations of contraceptives. For 
instance, the relatively high use of POP shown in this 
study in Sweden might be due to the fact that there are 
fewer contraindications for POP than CHC, and without 
the necessary medical support, it is safer to prescribe POP 
than CHC although POP has a lower continuation rate.42
It has been suggested that sexuality education 
programmes may lower teenage pregnancy rates by post-
poning the first sexual intercourse and by increasing 
both contraceptive user rates and quality of use. There 
is however a wide variety of programmes, and from the 
studies, it is difficult to draw conclusions about the extent 
to which programmes actually affect teenage pregnancy 
rates in practice.43 A Cochrane review of school-based 
sexuality education programmes found no evidence of 
an impact on pregnancy rates. There was however a low 
grade of evidence for an impact of incentives to stay in 
school on lower pregnancy rates. It should be noted that 
the majority of the studies included in the review were 
from low/middle-income countries.44 All the Nordic 
countries have compulsory sexuality education in schools 
but Finland has the most extensive programme of all the 
countries. Finland, with the current lowest abortion rate 
among the Nordic countries, witnessed an increase in the 
abortion rate in the mid-1990s just after the programme 
was no longer considered mandatory. After reinsti-
tuting a comprehensive compulsory sexuality education 
programme again in all Finnish schools in the early 
2000s, the abortion rate dropped again.45 In Finland, the 
programme is part of the specific school subject ‘Health 
science’ taught only by qualified teachers, in contrast to 
the other Nordic countries where sexuality education can 
be integrated in any other school subject and has a less 
well-defined curriculum.
It has also been suggested that subsidies of contra-
ceptives can lower pregnancy rates. However, Denmark, 
without any subsidies at all, has a higher contraceptive 
user rate and a lower abortion rate than Sweden, which 
offers subsidies for young women. This is in keeping with 
the findings from an English study where staying in school 
rather than the promotion of LARC seemed to have a 
higher impact on the teenage pregnancy rate.46 On the 
other hand, in the Contraceptive CHOICE Project where 
subsidies were combined with an extensive promotion 
of LARC in the St Louis area of the USA, the teenage 
pregnancy rate did decrease.47 Also, a recent study 
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from Finland where LARC was provided free of charge 
in one large community, but not in another, reported 
an increased uptake of LARC methods and a declining 
rate of abortions among all teenagers in the community 
with free-of-charge LARC.48 In Sweden, there have been 
temporary and regional declines in abortion rates when 
local subsidies have been launched together with promo-
tion campaigns for, for example, LARC, but the impact 
on the overall and long-term abortion rate has been diffi-
cult to detect.
In conclusion, we report steadily declining teenage 
birth and abortion rates, high user rate of hormonal 
contraceptives and an increasing use of LARC. A number 
of factors that could possibly influence contraceptive use 
and pregnancy rates have been discussed, such as easy 
access to youth clinics, promotion of LARC and sexuality 
education programmes. These factors would be of great 
interest to investigate further.
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